Affiliation:
1. Drug Metabolism & Pharmacokinetics Research Laboratories Daiichi Sankyo Co., Ltd. Tokyo Japan
Abstract
AbstractTrastuzumab deruxtecan (T‐DXd, DS‐8201a) is an antibody–drug conjugate, comprising an anti‐HER2 antibody at a drug‐to‐antibody ratio of 7–8 with the topoisomerase I inhibitor DXd. In this study, the concentrations of antibody‐conjugated DXd and total antibody were determined and observed to decrease over time following intravenous administration of T‐DXd to monkeys. The drug‐to‐antibody ratio of T‐DXd also decreased in a time‐dependent manner, which reached approximately 2.5 in 21 days after administration. It was suggested that antibody‐conjugated DXd of T‐DXd was relatively stable in vivo compared with that of other reported antibody–drug conjugates.
Subject
Pharmacology (medical),Pharmaceutical Science,Pharmacology,General Medicine